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Purpose. The purpose of this study is to investigate whether the clinicopathological biopsy ﬁndings can predict the oncological
outcome in patients who undergo radical prostatectomy. Materials and Methods. Between January 1997 and March 2006, 255
patients with clinically localized adenocarcinoma of the prostate (clinical T1-3N0M0) who had undergone retropubic radical
prostatectomy were enrolled in this study. None of the patients received neoadjuvant or adjuvant therapy. Clinicopathological
parameters were assessed to determine a predictive parameter of biochemical recurrence. Results. Of the total 255 patients, 77
showed biochemical recurrence during the follow-up period. The estimated 5-year overall survival, 5-year cause-speciﬁc survival,
and 5-year biochemical recurrence-free survival rates were 97.7%, 99.5%, and 67.3%, respectively. Multivariate analysis using the
Cox proportional hazards model showed that calculated cancer volume was an independent predictor among the preoperative
clinicopathological parameters (P<0.05). SVI and PSM were independent predictors among the postoperative parameters (SVI;
P<0.001,PSM;P = 0.049).Amongthesigniﬁcantpreoperativeandpostoperativeparameters,calculatedcancervolumeremained
anindependent predictive parameter inmultivariateanalysis (P<0.01).Conclusions. Tumor volume, as calculated by preoperative
parameters, is an independent predictor of biochemical recurrence in patients who had undergone radical prostatectomy.
1.Introduction
Radical prostatectomy has been the gold standard of deﬁni-
tive therapy for patients with localized prostate cancer for
years [1]. Now, not only laparoscopic radical prostatectomy,
but recently also robotic radical prostatectomy has remained
popular over the years all across the world [2, 3].
Prostate cancer patients have been able to choose
their primary treatment modality among several treatment
options since the technical development of radiation therapy
such as 3-dimensional conformal radiation therapy (3-
DCRT),intensitymodulatedradiationtherapy(IMRT),low-
dose-rate brachytherapy (LDR-brachytherapy), and high-
dose-rate brachytherapy (HDR-brachytherapy) [4]. If it is
possible to predict the oncological outcome based on the
clinicopathological ﬁndings at diagnosis, it will be possible
to choose the most suitable treatment option in patients who
receive deﬁnitive therapy.
The purpose of this study is to investigate whether the
clinicopathological biopsy ﬁndings can predict the oncolog-
ical outcome in patients who are undergoing radical prosta-
tectomy.
2.MaterialandMethods
Between January 1997 and March 2006, there were 577
patients who consecutively underwent retropubic radical2 Advances in Urology
prostatectomy at Nara Medical University Hospital and its
aﬃliate hospitals. Among all of these patients, 255 patients
who did not receive neoadjuvant or adjuvant therapy and
had clinically localized adenocarcinoma of the prostate
(clinical T1-3N0M0; 2002 UICC classiﬁcation [5]) were
enrolled in this retrospective study. The mean follow-up
period was 53 months (range: 12–127 months). The mean
age at surgery and PSA value at diagnosis were 67.4 years and
10.9ng/mL, respectively.
Patients’ course was followed every 3 to 6 months until 5
yearsaftersurgery,andthenevery6–12monthsthereafter.At
each visit, PSA was measured and digital rectal examination
was performed. If clinical recurrence was suspected, patients
underwent a bone scan, computed tomography, and mag-
netic resonance examination. Biochemical recurrence was
deﬁned as a PSA value of 0.2ng/mL or greater.
Regarding preoperative clinicopathological ﬁndings, age
at surgery, PSA at diagnosis, biopsy Gleason score, clinical
T stage, percent positive biopsy cores, risk classiﬁcation by
D’Amico et al. [6], and calculated cancer volume reported
by D’Amico et al. [7] were used to predict biochemical
recurrence. Patients were stratiﬁed by PSA level at diagnosis
of 10ng/mL or less, greater than 10ng/mL to 20ng/mL or
less, and greater than 20ng/mL, respectively, by Gleason
score (biopsy and surgical) of 6 or less, 7 and 8–10,
respectively. Patients were stratiﬁed by a volume of 2.0mL or
less, greater than 2.0mL to 4.0mL or less, and greater than
4.0mL, respectively. Patients were also stratiﬁed by positive
biopsy core of less than 34%, 34% or greater but less than
50%, and 50% or greater, respectively, and D’Amico risk
classiﬁcation [6] was used for risk classiﬁcation. Regarding
postoperative pathological ﬁndings, pathological T stage,
extraprostatic extension (EPE), seminal vesicle involvement
(SVI), positive surgical margin (PSM), and surgical Gleason
score were examined in the same manner.
Biochemical recurrence-free rate was calculated by the
Kaplan-Meier method. Comparison of the biochemical
recurrence-free rate stratiﬁed by clinicopathological param-
eters was tested by the log rank test. The Cox proportional
hazards model was used to determine the predictive param-
eter of biochemical recurrence among the preoperative
and the postoperative parameters both in univariate and
multivariate analyses. Finally, the Cox proportional hazards
model was used to determine the predictive parameter using
the signiﬁcant predictive parameters among the preoperative
and postoperative parameters in multivariate analysis. To
examine diﬀerences in categorical parameters, the chi-square
test was used. Mann-Whitney U test was used to examine
diﬀerences in continuous variables. All P values below 0.05
were considered to be statistically signiﬁcant.
Theinstitutionalreviewerboardapprovedthisretrospec-




Of the total 255 patients, 77 showed biochemical recurrence
during the follow-up period. Of these 77 patients, 2 patients
showed clinical recurrence, and 63 patients underwent
salvage therapy (44 patients: androgen deprivation therapy,
11 patients: radiotherapy, and 8 patients: both androgen
deprivation therapy and radiotherapy), while 14 patients
took a wait-and-see approach after biochemical recurrence.
The estimated 5-year overall survival, cause-speciﬁc survival
and biochemical recurrence-free survival rates were 97.7%,
99.5%, and 67.3%, respectively. The estimated 10-year
overall survival, cause-speciﬁc survival, and biochemical
recurrence-freesurvivalrateswere80.2%,99.5%,and56.2%,
respectively. Patients’ demographics are listed in Tables 1 and
2. PSA level at diagnosis, biopsy Gleason score, clinical T
stage, calculated cancer volume, percent positive biopsy core
andriskclassiﬁcationwerestatisticallyhigherinpatientswho
showed biochemical recurrence than in those who did not
show biochemical recurrence.
3.1. Biochemical Recurrence-Free Rate of Preoperative Clin-
icopathological Parameters. Regarding the clinical T stage,
the estimated 5-year biochemical recurrence-free rates of
T1a-b, T1c, T2, and T3a were 80.0%, 74%, 57%, and 51%,
respectively. There was a signiﬁcant diﬀerence between T1c
and T2 stage (P = 0.0379).
Stratiﬁed by the biopsy Gleason score, the estimated 5-
year biochemical recurrence-free rates of a Gleason score
of 6 or less, 7, and 8–10 were 76.2%, 68.2%, and 24.4%,
respectively. Patients with a Gleason score of 6 or less showed
a signiﬁcant higher biochemical recurrence-free rate than
those with a Gleason score of 7 and 8–10, respectively (P =
0.0377 and P<0.001). There was a signiﬁcant biochemical
recurrence-free rate diﬀerence between Gleason score 7 and
8–10 (P = 0.0159).
The estimated 5-year biochemical recurrence-free rates
of patients with a PSA level at diagnosis of 10ng/mL or
less, 10.1–20ng/mL, and greater than 20ng/mL were 74.4%,
65.7%, and 23.3%, respectively. There were signiﬁcant
diﬀerences between the 10ng/mL or less and the greater than
20ng/mL groups, and between the 10.1–20ng/mL and the
greater than 20ng/mL groups, respectively (P<0.0001 and
P = 0.0002).
Stratiﬁed by the percent positive core, the estimated
5-year biochemical recurrence-free rates of patients with
less than 34%, 34% to less than 50% and 50% or greater
were 75.3%, 55.0%, and 45.1%, respectively. There were
signiﬁcant diﬀerences between patients with less than 34%
and those with 50% or greater (P<0.0001).
Risk classiﬁcation also showed a signiﬁcant diﬀerence in
the biochemical recurrence-free rate. The estimated 5-year
biochemical recurrence-free rates of patients with a low risk,
an intermediate risk, and a high risk were 79.0%, 71.9% and
48.8%, respectively. The high-risk patient group showed a
signiﬁcantly higher biochemical recurrence rate compared
with the low- and intermediate-risk patient groups (P =
0.0004 and 0.0375).
Stratiﬁed by calculated cancer volume, the estimated
5-year biochemical recurrence-free rates of patients with
2.0mL or less, 2.1–4.0mL, and greater than 4.0mL were
81.1%, 51.0%, and 12.0%, respectively. Patients with 2.0mLAdvances in Urology 3






(n = 178) P value
Age 67.4 ±5.86 7 .1 ±5.46 7 .6 ± 5.9n . s . §
PSA at biopsy
(ng/mL)
Mean ± SD 10.9 ±7.21 4 .1 ±9.99 .6 ±5.2 <0.001§
10 or less 151 35 116
10–20 84 28 56
Greater than 20 20 14 6 <0.001∗
Biopsy Gleason score
6 or less 144 32 112
76 3 2 0 4 3
8–10 25 9 16
Unknown 23 9 14 <0.001∗
Clinical stage
T1 151 38 113
T2 102 38 64
T3 2 1 1 0.001∗
Calculated cancer
volume (mL)
2.0 or less 112 17 95
2.0–4.0 47 17 30
Greater than 4.0 31 20 11
unknown 65 23 42 <0.001∗
Mean ± SD 2.48 ±2.38 4.01 ±3.38 1.88 ±1.45 <0.001§
% positive biopsy core
Less than 34 158 38 120
34–50 22 6 16
50 or greater 66 32 34
unknown 9 1 8 0.001∗
Biochem. recur.: Biochemical recurrence. ∗Chi-square test and §Mann Whitney U test.
or less showed a signiﬁcantly lower biochemical recurrence-
free rate than those with 2.1–4.0mL and greater than 4.0mL,
respectively (P = 0.0008, and P<0.0001). Patients with
2.1–4.0mL also showed a signiﬁcantly lower biochemical
recurrence rate than those with greater than 4.0mL (P =
0.0109).
3.2. Biochemical Recurrence-Free Rate of Postoperative Patho-
logical Parameters. Regarding the pathological parameters
obtained at surgery, the pathological Gleason score and the
pathological T stage were statistically higher in patients who
showed biochemical recurrence, and the number of patients
who showed EPE, PSM, or SVI was also statistically greater
than those without biochemical recurrence.
The estimated 5-year biochemical recurrence-free rates
of pathological T0, T2, T3a, T3b, and T4 were 80.0%, 76.1%,
57.0%, 0%, and 0%, respectively. A log rank test showed
signiﬁcant diﬀerences among the pathological T stages.
Regarding EPE, the estimated 5-year biochemical recur-
rence-free rates of patients with positive and negative EPE
were 72.8% and 53.2%, respectively (P = 0.0167). Regarding
SVI, the estimated 5-year biochemical recurrence-free rates
of patients with positive and negative SVI were 71.0% and
0%, respectively (P<0.0001). Regarding the surgical margin
status,theestimated5-yearbiochemicalrecurrence-freerates
of patients with a positive and a negative surgical margin
were 76.0% and 47.6%, respectively (P<0.0001).
3.3. Multivariate Analysis Using Preoperative and Postopera-
tive Clinicopathological Parameters. Regarding the preoper-
ative clinicopathological parameters, biopsy Gleason score,
clinical stage, PSA at biopsy, percent positive cores, and
calculated cancer volume were independent predictors of
biochemical recurrence in univariate analysis. Multivariate
analysis using the Cox proportional hazards model showed
that the calculated cancer volume was the independent
predictor (P<0.05) (Table 3).
Regarding postoperative pathological parameters, surgi-
cal Gleason score, EPE, SVI, and PSM were independent
predictors of biochemical recurrence in univariate analysis.4 Advances in Urology






(n = 178) P value
Surgical Gleason score
6 122 30 92
78 9 2 9 6 0
8–10 23 13 10
Unknown 21 5 16 0.009∗
Pathological stage
T0 5 1 4
T2 170 40 130
T3a 68 25 43
T3b 10 9 1
T4 2 2 0 0.001∗
EPE
Positive 74 30 44
Negative 181 47 134 0.017∗
Surgical margin
Positive 64 29 35
Negative 164 35 129
Unknown 33 13 20 <0.001∗
SVI
Positive 12 11 1
Negative 243 66 177 <0.001∗
Biochem. recur.: biochemical recurrence, EPE: extraprostatic extension, SVI: seminal vesicle involvement.
∗Chi-square test and §Mann Whitney U test.
Multivariate analysis using the Cox proportional hazards
model showed that SVI and PSM were the independent
predictors (SVI; P<0.001, PSM; P = 0.049) (Table 4).
We conducted multivariate analysis using calculated
cancer volumes, SVI and PSM, which were signiﬁcant
predictors in multivariate analysis of both preoperative and
postoperative parameters. Consequently, SVI and PSM lost
their signiﬁcance and calculated cancer volume was the
independent predictor (P<0.01) (Table 5).
4. Discussion
Many investigators have tried to determine independent
predictors of biochemical recurrence in patients who had
undergone radical prostatectomy [8–20]. Among the pre-
operative clinicopathological parameters, PSA at biopsy,
biopsy Gleason score, clinical stage, percent biopsy core, risk
classiﬁcation, and calculated tumor volume were reported
as independent predictors, while pathological stage, EPE,
SVI, PSM, tumor volume, and surgical Gleason score were
reported as independent predictors of biochemical recur-
rence among the postoperative pathological parameters.
Regarding the predictive potency of tumor volume in
biochemical recurrence after radical prostatectomy, some
investigators take an aﬃrmative stance [17, 21], while others
postulate a dismissive view [22–25]. Taking the aﬃrmative
stance, the prediction of the tumor volume of prostate
cancerleadstothepredictionofbiochemicalrecurrenceafter
radical prostatectomy. This prediction is not only useful in
patients who undergo radical prostatectomy, but also those
who receive deﬁnitive radiation therapy (e.g., IMRT, high-
dose-rate and low-dose-rate brachytherapy). An attempt to
calculate the tumor volume of prostate cancer has been
reported by several investigators [17–21].
In the present study, we calculated the tumor volume
according to the equation reported by D’Amico et al. [7].
Using the preoperative parameters, tumor volume had an
independent potency of prediction of biochemical recur-
rence in multivariate analysis. Using the postoperative pa-
rameters, SVI and PSM remained as independent predictors.
Using these three independent preoperative and postoper-
ative parameters, only tumor volume remained signiﬁcant.
SVI and PSM were marginal predictive values (P = 0.073,
and 0.058, resp.). On the other hand, Chan and Stamey
veriﬁed the equation to calculate tumor volume reported
by D’Amico, and they reported that there was a signiﬁcant
correlation between the calculated cancer volume and the
actual total cancer volume (r = 0.537; P<0.0001) [22].
However, they concluded that PSA was a much stronger
predictor of cancer volume than calculated prostate cancer
volume.
Our present study has several limitations, namely, the
number of patients is small (n = 255), the mean follow-
up period is short (53 months), and we have not calculated
the tumor volume by using radical prostatectomy specimens
yet. The correlation between calculated tumor volume and
true tumor volume in our patients is unknown. However,
the calculated tumor volume indeed had an independentAdvances in Urology 5
Table 3: Univariate and multivariate analysis in preoperative clinicopathological parameters.
Parameter
Univariate Multivariates
Hazard ratio 95% C.I. P value Hazard ratio 95% C.I. P value
Age (continuous) 0.984 0.944–1.027 0.462 N.A.
Biopsy Gleason
score
6o rl e s s 1 1
7 1.269 0.663–2.430 0.472 0.658 0.281–1.543 0.336
8–10 4.103 2.199–7.656 <0.001 0.925 0.312–2.739 0.888
Clinical stage
T1 1 1
T2 1.719 1.048–2.819 0.032 1.191 0.652–2.177 0.567
T3 4.298 0.583–31.654 0.152 4.037 0.507–32.121 0.187
PSA at biopsy
(ng/mL)
10 or less 1 1
10–20.0 1.543 0.892–2.668 0.121 0.961 0.398–2.324 0.930
Greater than 20 4.555 2.314–8.965 <0.001 0.892 0.258–3.089 0.857
%p o s i t i v ec o r e s
Less than 34 1 1
34–50 1.139 0.444–2.920 0.787 1 0.333–2.999 1.000
50 or greater 2.340 1.384–3.956 0.002 1.807 0.949–3.444 0.072
Calculated cancer
volume (mL)
2.0 or less 1 1
2.0–4.0 2.716 1.323–5.577 0.006 3.022 1.144–7.981 0.026
Greater than 4.0 7.116 3.595–14.085 <0.001 6.962 1.755–27.624 0.006
N.A.: not available. C.I: conﬁdence interval.
Table 4: Univariate and multivariate analysis in postoperative clinicopathological parameters.
Parameter
Univariate Multivariates
Hazard ratio 95% C.I. P value Hazard ratio 95% C.I. P value
Surgical Gleason
score
6o rl e s s 1 1
7 1.329 0.748–2.360 0.332 0.884 0.458–1.706 0.713
8–10 3.345 1.716–6.522 <0.001 1.858 0.840–4.113 0.126
EPE
Negative 1 1
Positive 2.026 1.232–3.331 0.005 1.337 0.735–2.431 0.342
SVI
Negative 1 1
Positive 8.425 4.219–16.825 <0.001 4.615 1.996–10.672 <0.001
Surgical margin
Negative 1 1
Positive 2.943 1.704–5.080 <0.001 1.902 1.001–3.614 0.049
EPE: extraprostatic extentions, SVI: seminal vesicle involvement, C.I.: conﬁdence interval.6 Advances in Urology
Table 5: Univariate and multivariate analysis in both preoperative and postoperative clinicopathological parameters.
Univariate Multivariates
Parameter Hazard ratio 95% C.I. P value Hazard ratio 95% C.I. P value
SVI
Negative 1 1
positive 8.425 4.219–16.825 <0.001 2.460 0.919–6.580 0.073
Surgical marrgin
Negative 1 1
positive 2.943 1.704–5.080 <0.001 2.057 0.975–4.339 0.058
Calculated cancer
volume (mL)
2.0 or less 1 1
2.1–4.0 2.716 1.323–5.577 0.006 3.191 1.397–7.291 0.006
Greater than 4.0 7.116 3.595–14.058 <0.001 4.498 1.749–11.564 0.002
SVI: seminal vesicle involvement, C.I: conﬁdence Interval.
predictive potency for biochemical recurrence after radical
prostatectomy in multivariate analyses not only among
preoperative parameters, but also pre- and postoperative
parameters.
Since the progress in deﬁnitive radiation therapy, pre-
treatment predictive parameters of oncological outcomes
after deﬁnitive therapy in patients with localized and locally
advanced prostate cancer are expected.
5. Conclusion
The calculated tumor volume by preoperative parameters
can be an independent predictor of recurrence for patients
and will experience biochemical recurrence.
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